Vantage logo

What’s next for relatlimab?

The Lag3 inhibitor is now approved in melanoma, but Bristol looks unlikely to stop there in its search for a safer Yervoy.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.